Chronic administration of the delta opioid receptor agonist (+)BW373U86 and antidepressants on behavior in the forced swim test and BDNF mRNA expression in rats

Psychopharmacology

Volumn 183, Issue 1, 2005, Pages 31-40

  Torregrossa, Mary M ^a   Folk, John E ^b   Rice, Kenner C ^b   Watson, Stanley J ^a,c   Woods, James H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

(+)BW373U86; Antidepressant; BDNF; Delta opioid receptor; Forced swim test; In situ hybridization

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; DELTA OPIATE RECEPTOR AGONIST; DESIPRAMINE; FLUOXETINE; MESSENGER RNA; TRANYLCYPROMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DENTATE GYRUS; DRUG EFFECT; FORCED SWIMMING TEST; FRONTAL CORTEX; HIPPOCAMPUS; HISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BENZAMIDES; BRAIN-DERIVED NEUROTROPHIC FACTOR; BUPROPION; CEREBRAL CORTEX; DESIPRAMINE; DRUG TOLERANCE; FLUOXETINE; HIPPOCAMPUS; MALE; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, DELTA; RNA, MESSENGER; SWIMMING; TIME FACTORS;

EID: 26944467560     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-0113-5     Document Type: Article

References (29)

1. Azar MR, Ahmed SH, Lintz R, Gutierrez T, Stinus L, Koob GF (2004) A non-invasive gating device for continuous drug delivery that allows control over the timing and duration of spontaneous opiate withdrawal. J Neurosci Methods 135:129-135
2. Bishop MJ, McNutt RW (1995) An efficient synthesis of the benzhydrylpiperazine delta opioid agonist (+)BW373U86. Bioorg Med Chem Lett 5:1311-1314
3. Brandt MR, Furness MS, Rice KC, Fischer BD, Negus SS (2001) Studies of tolerance and dependence with the delta-opioid agonist SNC80 in rhesus monkeys responding under a schedule of food presentation. J Pharmacol Exp Ther 299:629-637
4. Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH (2002a) Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant effects in Sprague-Dawley rats. Psychopharmacology 164:42-48
5. Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH (2002b) Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology 26:744-755
6. Comer SD, Hoenicke EM, Sable AI, McNutt RW, Chang K-J, DeCosta BR, Mosberg HI, Woods JH (1993) Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice. J Pharmacol Exp Ther 215:127-134
7. Coppell AL, Pei Q, Zetterstrom TSC (2003) Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology 44:903-910
8. DeFoubert G, Carney SL, Robinson CS, Destexhe EJ, Tomlinson R, Hicks CA, Murray TK, Gaillard JP, Deville C, Xhenseval V, Thomas CE, O'Neill MJ, Zetterstrom TSC (2004) Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience 128:597-604
9. Detke MJ, Johnson J, Lucki I (1997) Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression. Exp Clin Psychopharmacol 5:107-112
10. Dias BG, Banerjee SB, Duman RS, Vaidya VA (2003) Differential regulation of brain derived neurotrophic factor transcripts by antidepressant treatments in the adult rat brain. Neuropharmacology 45:553-563
11. Duman RS (2004) Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromol Med 5:11-25
12. Filliol D, Ghozland S, Chluba J, Martin M, Matthes HWD, Simonin F, Befort K, Gaveriaux-Ruff C, Dierich A, LeMeur M, Valverde O, Maldonado R, Kieffer BL (2000) Mice deficient for delta and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25:195-200
13. Hong EJ, Rice KC, Calderon S, Woods JH, Traynor JR (1998) Convulsive behavior of nonpeptide delta opioid ligands: comparison of SNC80 and BW373U86 in mice. Analgesia 3:269-276
14. Isackson PJ, Huntsman MM, Murray KD, Gall CM (1991) BDNF mRNA expression is increased in adult rat forebrain after limbic seizures: temporal patterns of induction distinct from NGF. Neuron 6:937-948
15. Jacobsen JPR, Mork A (2004) The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels. Brain Res 1024:183-192
16. Jutkiewicz EM, Rice KC, Traynor JR, Woods JH (2005) Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats. Psychopharmacol DOI 10.1007/s00213-005-0138-9
17. Kramer HK, Onoprishvili I, Andria ML, Hanna K, Sheinkman K, Haddad LB, Simon EJ (2002) Delta opioid activation of the mitogen-activated protein kinase cascade does not require transphosphorylation of receptor tyrosine kinases. BMC Pharmacol 2:5-14
18. Mansour A, Thompson RC, Akil H, Watson SJ (1993) Delta opioid receptor mRNA distribution in the brain: comparison to delta receptor binding and proenkephalin mRNA. J Chem Neuroanat 6:351-362
19. Middlemas DS, Lindberg RA, Hunter T (1991) TrkB, a neural receptor protein-tyrosine kinase: evidence for a full-length and two truncated receptors. Mol Cell Biol 11:143-153
20. Miro X, Perez-Torres S, Artigas F, Puigdomenech P, Palacios JM, Mengod G (2002) Regulation of cAMP phosphodiesterase mRNAs expression in rat brain by acute and chronic fluoxetine treatment. An in situ hybridization study. Neuropharmacology 43:1148-1157
21. Nibuya M, Morinobu S, Duman RS (1995) Regulation of BDNF and TrkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15:7539-7547
22. Persson AI, Thorlin T, Bull C, Eriksson PS (2003) Opioid-induced proliferation through the MAPK pathway in cultures of adult hippocampal progenitors. Mol Cell Neurosci 23:360-372
23. Russo-Neustadt A, Beard RC, Cotman CW (1999) Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology 21:679-682
24. Saarelainen T, Vaittinen S, Castren E (2001) TrkB-receptor activation contributes to the kainate-induced increase in BDNF mRNA synthesis. Cell and Mol Neurobio 21:429-435
25. Saitoh A, Kimura Y, Suzuki T, Kawai K, Nagase H, Kamei J (2004) Potential anxiolytic and antidepressant-like activities of SNC 80, a selective delta-opioid agonist, in behavioral models in rodents. J Pharmacol Sci 95:374-380
26. Shirayama Y, Chen AC-H, Nakagawa S, Russell DS, Duman RS (2002) Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 22:3251-3261
27. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM (1997) Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 56:131-137
28. Torregrossa MM, Isgor C, Folk JE, Rice KC, Watson SJ, Woods JH (2004) The delta opioid receptor agonist (+)BW373U86 regulates BDNF mRNA expression in rats. Neuropsychopharmacology 29:649-659
29. Wu X, Zhu D, Jiang X, Okagaki P, Mearow K, Zhu G, McCall S, Banaudha K, Lipsky RH, Marini AM (2004) AMPA protects cultured neurons against glutamate excitotoxicity through phosphotidylinositol 3-kinase-dependent activation in extracellular-regulated kinase to upregulate BDNF gene expression. J Neurochem 90:807-818